> top > docs > PubMed:21605817 > annotations

PubMed:21605817 JSONTXT

Annnotations TAB JSON ListView MergeView

Allie

Id Subject Object Predicate Lexical cue
SS1_21605817_1_0 49-80 expanded denotes Epidermolysis bullosa acquisita
SS2_21605817_1_0 82-85 abbr denotes EBA
AE1_21605817_1_0 SS1_21605817_1_0 SS2_21605817_1_0 abbreviatedTo Epidermolysis bullosa acquisita,EBA

PubmedHPO

Id Subject Object Predicate Lexical cue
T1 93-103 HP_0002960 denotes autoimmune
T2 104-114 HP_0008066 denotes blistering
T3 469-476 HP_0008066 denotes blister
T4 761-780 HP_0002960 denotes autoimmune diseases
T5 761-771 HP_0002960 denotes autoimmune

Inflammaging

Id Subject Object Predicate Lexical cue
T1 0-48 Sentence denotes Pathogenesis of epidermolysis bullosa acquisita.
T2 49-181 Sentence denotes Epidermolysis bullosa acquisita (EBA) is an autoimmune blistering skin disease characterized by autoantibodies to type VII collagen.
T3 182-268 Sentence denotes Clinically, a noninflammatory and an inflammatory variant of EBA can be distinguished.
T4 269-374 Sentence denotes Despite major achievements in the understanding of EBA, current therapeutic options are far from optimal.
T5 375-564 Sentence denotes However, with an emerging and more detailed understanding of the events ultimately leading to blister formation in EBA, novel therapeutic options may become available for patients with EBA.
T6 565-781 Sentence denotes Therefore, this article reviews the current understanding of the pathogenesis of EBA and may indicate possible avenues towards a more targeted therapy for EBA and possibly other antibody-mediated autoimmune diseases.
T1 0-48 Sentence denotes Pathogenesis of epidermolysis bullosa acquisita.
T2 49-181 Sentence denotes Epidermolysis bullosa acquisita (EBA) is an autoimmune blistering skin disease characterized by autoantibodies to type VII collagen.
T3 182-268 Sentence denotes Clinically, a noninflammatory and an inflammatory variant of EBA can be distinguished.
T4 269-374 Sentence denotes Despite major achievements in the understanding of EBA, current therapeutic options are far from optimal.
T5 375-564 Sentence denotes However, with an emerging and more detailed understanding of the events ultimately leading to blister formation in EBA, novel therapeutic options may become available for patients with EBA.
T6 565-781 Sentence denotes Therefore, this article reviews the current understanding of the pathogenesis of EBA and may indicate possible avenues towards a more targeted therapy for EBA and possibly other antibody-mediated autoimmune diseases.